Associated tags: Drug development, Research, Doctor of Philosophy, Sanofi, Fine chemical, CBO, Patient, Seal Rock, History, Genome, Cell therapy, Molecular and Cellular Biology, Revitalize American Manufacturing and Innovation Act of 2013, Clinical Trials, Business development, IDM, Oncology, Science, Other Science, Pharmaceutical, Health
Locations: FRANCE, EUROPE, ERNST
Research,
Managed Care,
Professional Services,
Pharmaceutical,
Fitness & Nutrition,
Clinical Trials,
Science,
Biotechnology,
Finance,
Other Science,
Health,
Diabetes,
Multimedia,
Patient,
Growth,
MOA,
Pharma,
Pharmaceutical industry 4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors.
Key Points:
- 4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors.
- View the full release here: https://www.businesswire.com/news/home/20240424933193/en/
With this funding, 4P-Pharma's shareholders renew their confidence in the company's drug regeneration model for untreated serious diseases.
- They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma's SPVs, underlying the robust potential of the company's business model.
- It attests to the strength of our model for delivering first-in-class treatments for people suffering from untreated serious diseases."
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Health,
Clinical Trials,
Other Health,
Euronext Paris,
Initial public offering,
Financial management,
Multimedia,
Financial audit,
Ernst & Young,
Senior,
Growth,
EY,
CFO 4P-Pharma, a clinical-stage biotech based in Lille dedicated to developing curative therapies for serious untreated diseases, is thrilled to announce the appointment of Jérôme Vailland as Chief Financial Officer (CFO) for 4P-Pharma and its subsidiaries.
Key Points:
- 4P-Pharma, a clinical-stage biotech based in Lille dedicated to developing curative therapies for serious untreated diseases, is thrilled to announce the appointment of Jérôme Vailland as Chief Financial Officer (CFO) for 4P-Pharma and its subsidiaries.
- View the full release here: https://www.businesswire.com/news/home/20240314228336/en/
Jérôme Vailland 4P-Pharma Chief Financial Officer (Photo: Business Wire)
Jérôme Vailland built a solid career with significant contributions at Ernst & Young (EY), where he worked for 10+ years.
- Following his strong experience at EY, Jérôme joined Horama, now Coave Therapeutics, in 2016, serving as Chief Financial Officer.
- Regarding his appointment as Chief Financial Officer, Jérôme Vailland said, "I am thrilled to join 4P-Pharma at a decisive moment, especially with two drug candidates prepared to enter Phase II clinical trials.
Retrieved on:
Tuesday, September 5, 2023
Research,
Clinical Trials,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Other Science,
Science,
Oncology,
IDM,
Business development,
Revitalize American Manufacturing and Innovation Act of 2013,
Doctor of Philosophy,
Molecular and Cellular Biology,
Cell therapy,
Multimedia,
Genome,
History,
Seal Rock,
Patient,
CBO,
Growth,
Fine chemical,
Marketing,
Management,
Sanofi,
ESSEC During the latest strategic board meeting, the appointment of Didier Landais as the new CEO of 4P-Pharma was confirmed.
Key Points:
- During the latest strategic board meeting, the appointment of Didier Landais as the new CEO of 4P-Pharma was confirmed.
- View the full release here: https://www.businesswire.com/news/home/20230905514097/en/
Founded in 2014 by Revital Rattenbach, 4P-Pharma is entering a new era of its development.
- On September 1st, 2023, Didier Landais succeeds Revital Rattenbach as CEO of 4P-Pharma.
- As CEO, Didier Landais holds the responsibility for the company's overall strategy in terms of science, partnerships, and external growth.
